Drug intelligence / Profile preview

ALM-502

Development stage: Preclinical
Lead developer: Almac Discovery
Modality: Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ALM-502 is a biparatopic antibody-drug conjugate (ADC) developed by Almac Discovery for the treatment of various solid tumors. It utilizes VHH single-domain antibody binders (nanobodies) engineered into a biparatopic format and fused to a human Fc (hFc) domain. The ADC targets Alkaline Phosphatase Placental (ALPP) and Alkaline Phosphatase Placental Like 2 (ALPPL2), which are GPI-anchored cell-surface proteins overexpressed in cancers such as high-grade serous ovarian cancer (HGSOC), pancreatic, gastric, and bladder cancers, while maintaining minimal expression in normal tissues. ALM-502 is conjugated to a monomethyl auristatin E (MMAE) cytotoxic payload via a protease-cleavable valine-citrulline (vc) linker. The biparatopic design is specifically engineered to enhance tumor cell binding, internalization, and lysosomal trafficking compared to traditional monospecific ADCs, leading to potent anti-tumor efficacy.

Other names: ALPP biparatopic ADC

Targets

TUBB (Tubulin (alpha and beta subunits))ALPG (Alkaline phosphatase, placental-like 2)ALPP (Alkaline phosphatase, placental type)

Beyond the preview

Go deeper on ALM-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM-502.

Explore the full profile